
China controls world's rare earth supply chains: What are rare earth elements and why world can't function without them? Explained
(EVs), and clean energy may face critical challenges due to its limited domestic production of rare earth elements (REEs), despite holding sizable reserves.
Tired of too many ads? go ad free now
China continues to dominate the global REE supply chain, controlling over 90 per cent of the world's processing and magnet-making capacity, reported ET.
Rare earths, 17 elements with unique magnetic, luminescent, and electrochemical properties, are essential for a wide range of high-tech and green energy products. From permanent magnets in EV motors and wind turbines to phosphors in LED lights and data storage in MRI machines, these materials are foundational to next-generation technologies.
Here's how individual elements are used:
Neodymium (Nd): Permanent magnets in motors, headphones, microphones, hard drives, speakers
Praseodymium (Pr): Magnets (with Nd), aircraft engines, fibre optic cables
Dysprosium (Dy): Improves heat resistance in magnets, used in EV motors, hard drives, earbuds
Terbium (Tb): Phosphors for green colour in displays and lighting
Samarium (Sm): High-strength magnets for headphones, microwave devices, small motors
Europium (Eu): Red phosphors for displays and LED lights
Yttrium (Y): Phosphors for LED and CRT displays, laser devices
Gadolinium (Gd): Used in data storage and MRI machines
Lanthanum (La): Rechargeable batteries, lenses in cameras/smartphones, glass additives
Cerium (Ce): Polishing compounds for glass, catalysts, and phosphors
Erbium (Er): Optical amplifiers in fibre optic communication
Other REEs, Scandium, Holmium, Thulium, Lutetium, Ytterbium, Promethium, are vital in specialised lasers, sensors, electronic devices, and medical imaging systems.
According to ET, China alone accounts for nearly 70 per cent of global rare earth mining, with countries like the US (12 per cent), Myanmar (10 per cent), and Australia (8 per cent) following distantly.
India, though possessing around 6–7 million metric tonnes of reserves, about 6–7 per cent of the global total, contributes less than 1 per cent to the world's annual output.
This creates a major vulnerability for Indian manufacturers. Any disruption or restriction in supply from China could severely impact production lines, especially in EVs, smartphones, and defence systems. As per ET, this gives Beijing immense leverage.
While the US has tried building its own capacity in light rare earths like neodymium and cerium, China remains the primary source for most critical elements, including dysprosium, terbium, and yttrium.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
2 hours ago
- Time of India
Trump imposes 25% tariff on India Tata Motors' $4.5 Bn Iveco buyout
Trump has slapped a 25% tariff on Indian exports starting August 1, citing unfair trade and Russia ties. Markets reacted sharply as hopes for a full deal dimmed. Meanwhile, Tata Motors is set to acquire Italian truckmaker Iveco in a $4.5 billion buyout its biggest global deal ever. Watch the top 2 stories on Two Sharp with ET Show more Show less


Economic Times
3 hours ago
- Economic Times
Synergy Marine appoints Indian Vikas Trivedi as Co-CEO for ship management
(Catch all the Business News, Breaking News, Budget 2025 Events and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online.


Economic Times
3 hours ago
- Economic Times
Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini Piramal
Agencies About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan. Piramal Healthcare will focus on organic expansion as its primary growth driver for the next 4-5 years, while it looks for licensing of product acquisition deals in both complex hospital generics and consumer healthcare business, chairperson Nandini Piramal told ET in an reiterated the company's revenue target of $2 billion by FY30 despite macroeconomic volatility and sector-specific headwinds.'Our network of facilities is well-balanced and as people think about diversifying supply chains, and even think of going back to the US, I think we are well set for that. Our focus on differentiated offerings such as antibody-drug conjugate (ADCs) is seeing growth. Overall, the other businesses are also on track for that growth,' she is an area of pharmaceutical research that focuses on creating targeted cancer therapies. Talking about the current global headwinds, Piramal said near-term macro-economic uncertainty and biotech funding volatility in the US are some of the significant risk factors to watch out for in the months ahead. On Monday, the company announced its first quarter results with a net loss of Rs 82 crore in Q1 FY26 versus net loss of Rs 89 crore a year ago. Revenue from operations fell 1% year-on-year to Rs 1,934 crore. EBITDA margin for Q1 FY26 was 9% versus 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and ahead, Piramal said growth will be balanced between India, US and UK. The focus will be on broadening the customer base and getting new company is investing $90 million to expand two of its US facilities in Lexington and Lexington capability will come online in 2027, she said, and play a vital role in the company's integrated antibody-drug conjugate (ADC) development and manufacturing program.